research 265 Modulation of disease-central cytokine pathways with TAK-279, a highly selective oral tyrosine kinase 2 (TYK2) inhibitor, defines clinical response in patients with psoriasis
TAK-279 effectively reduces psoriasis symptoms and is safe.
Incomplete name
St Helens, United Kingdom
Incomplete name
Stockport, United Kingdom
Incomplete name
Southend-on-Sea, United Kingdom
Incomplete name
Delft, Netherlands
Incomplete name
Banstead, United Kingdom
Incomplete name
Mumbai, Maharashtra, India




